Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BIIB
stocks logo

BIIB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
2.21B
-9.86%
1.748
-49.19%
2.26B
-7.13%
3.485
+15.4%
2.37B
-10.39%
3.829
-30%
Estimates Revision
The market is revising Upward the revenue expectations for Biogen Inc. (BIIB) for FY2025, with the revenue forecasts being adjusted by 0.22% over the past three months. During the same period, the stock price has changed by 29.37%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.22%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.26%
In Past 3 Month
Stock Price
Go Up
up Image
+29.37%
In Past 3 Month
Wall Street analysts forecast BIIB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIIB is 184.00 USD with a low forecast of 149.00 USD and a high forecast of 250.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
Wall Street analysts forecast BIIB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIIB is 184.00 USD with a low forecast of 149.00 USD and a high forecast of 250.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
10 Hold
0 Sell
Moderate Buy
Current: 181.980
sliders
Low
149.00
Averages
184.00
High
250.00
Current: 181.980
sliders
Low
149.00
Averages
184.00
High
250.00
Piper Sandler
Neutral
maintain
$118 -> $157
2025-11-21
Reason
Piper Sandler
Price Target
$118 -> $157
2025-11-21
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on Biogen to $157 from $118 and keeps a Neutral rating on the shares. The firm notes that Biogen shares have certainly participated in the broader rally of the biopharma space in recent months, with the stock up about 35% since the beginning of Q3 2025.
Stifel
Hold -> Buy
upgrade
$144 -> $202
2025-11-06
Reason
Stifel
Price Target
$144 -> $202
2025-11-06
upgrade
Hold -> Buy
Reason
Stifel upgraded Biogen to Buy from Hold with a price target of $202, up from $144, following the Q3 report. The firm believes the stock's risk/reward is shifting favorably with clinical catalysts ahead. The upgrade is not a call on the base business, as Biogen's Q3 results were mixed and Q4 "will be just okay," the analyst tells investors in a research note. However, Stifel believes Biogen shares can trade higher in the next 12 months due to a "narrative shift" in Alzheimer's. This will be supported by potential success of Eli Lily's TRAILBLAZER-ALZ 3 trial, which could fundamentally change the way doctors and investors think about amyloid beta antibodies, the analyst tells investors in a research note. Biogen offers "unique optionality even if clinical catalysts still have risks," contends the firm.
Bernstein
Bernstein
Market Perform
maintain
$155 -> $157
2025-11-03
Reason
Bernstein
Bernstein
Price Target
$155 -> $157
2025-11-03
maintain
Market Perform
Reason
Bernstein raised the firm's price target on Biogen to $157 from $155 and keeps a Market Perform rating on the shares following quarterly results. The performance of multiple sclerosis Franchise and to a lesser extent Anti-CD20 drove the revenue beat, outpacing consensus by 14% and 10%, respectively, the firm notes. Leqembi's miss took away the shine from this beat, and while this can be partly explained by channel dynamics, the broader competitive environment looks increasingly challenging, Bernstein adds.
Baird
Outperform
to
NULL
downgrade
$255 -> $250
2025-10-31
Reason
Baird
Price Target
$255 -> $250
2025-10-31
downgrade
Outperform
to
NULL
Reason
Baird lowered the firm's price target on Biogen to $250 from $255 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results where its beat was driven by MS as its launch products are showing slow growth.
Jefferies
Andrew Tsai
Buy
initiated
$190
2025-09-24
Reason
Jefferies
Andrew Tsai
Price Target
$190
2025-09-24
initiated
Buy
Reason
Jefferies analyst Andrew Tsai initiated coverage of Biogen with a Buy rating and $190 price target. The firm believes investor expectations are low with Biogen's key risks generally understood. The shares can "grind higher" on any positive developments in 2026, including a Leqembi sales acceleration in Alzheimer's, resiliency of the base business and late-stage pipeline success, the analyst tells investors in a research note. Jefferies sees a favorable risk/reward for Biogen at current levels, saying the stock is trading close to "no-pipeline" value.
Piper Sandler
Neutral
maintain
$115 -> $118
2025-08-14
Reason
Piper Sandler
Price Target
$115 -> $118
2025-08-14
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on Biogen to $118 from $115 and keeps a Neutral rating on the shares. The firm says that regarding the two amyloid beta-directed therapies on the market, it is becoming clear that competitive dynamics are not at all amounting to a zero-sum game. That's the good news. That said, Piper continues to see a commercial footprint for the category that is quite limited in the context of the sheer size of the Alzheimer's disease space.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Biogen Inc (BIIB.O) is 14.30, compared to its 5-year average forward P/E of 14.11. For a more detailed relative valuation and DCF analysis to assess Biogen Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
14.11
Current PE
14.30
Overvalued PE
17.51
Undervalued PE
10.71

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
10.30
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
12.70
Undervalued EV/EBITDA
7.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.42
Current PS
0.00
Overvalued PS
4.23
Undervalued PS
2.61
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

BIIB News & Events

Events Timeline

(ET)
2025-12-03
18:20:00
Eisai and Biogen Announce Latest Findings on Lecanemab for Alzheimer's Treatment
select
2025-12-02 (ET)
2025-12-02
16:50:00
Eisai and Biogen Present Lecanemab's Efficacy in Alzheimer's Disease at Conference
select
2025-11-28 (ET)
2025-11-28
06:19:51
Eisai submits new drug application for subcutaneous Leqembi in Japan
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-04NASDAQ.COM
PinnedEisai and Biogen Highlight Sustained Advantages of LEQEMBI for Early Alzheimer's Disease

  • New Findings on LEQEMBI: Eisai and Biogen presented findings at the CTAD Conference indicating that LEQEMBI maintenance treatment can potentially delay progression from Mild Cognitive Impairment to moderate Alzheimer's disease by up to 8.3 years in early-stage patients with low amyloid levels.

  • Safety and Efficacy Data: New safety and efficacy data for the subcutaneous formulation of LEQEMBI were shared, highlighting its approval in the U.S. for maintenance treatment in August 2025, with an application for initiation treatment submitted in November 2025.

  • International Approval Applications: Eisai has also submitted an application for the approval of the subcutaneous injectable formulation in Japan in November 2025, expanding its reach in Alzheimer's treatment.

  • Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.

[object Object]
Preview
9.0
12-04PRnewswire
Eisai and Biogen Present LEQEMBI Data Indicating 8.3-Year Delay in Alzheimer's Progression
  • Significant Efficacy: Recent findings indicate that early treatment with LEQEMBI can delay the progression of Alzheimer's disease by up to 8.3 years in low-amyloid patients, highlighting the drug's critical role in early intervention and potentially reshaping treatment strategies.
  • Enhanced Safety: The latest clinical trials show that the subcutaneous formulation of LEQEMBI demonstrates comparable efficacy and safety to intravenous administration, with a systemic infusion reaction rate of 0%, which is expected to improve patient adherence and treatment experience.
  • Regulatory Progress: The rolling supplemental Biologics License Application for LEQEMBI was completed in November 2025, which is anticipated to expedite its market access in the U.S. and Japan, further solidifying Eisai and Biogen's leadership in Alzheimer's treatment.
  • Clinical Research Support: This study is based on the Clarity AD open-label extension trial and 16 clinical studies, providing robust data that emphasizes LEQEMBI's potential in slowing disease progression, likely attracting more investment and attention.
[object Object]
Preview
9.0
12-04Globenewswire
Eisai and Biogen Present LEQEMBI Efficacy Data, Potentially Delaying Alzheimer's Progression by 8.3 Years
  • Significant Efficacy: Recent data indicates that LEQEMBI treatment can extend the time for patients with Mild Cognitive Impairment (MCI) to progress to moderate Alzheimer's Disease (AD) to 18.4 years, an increase of 8.3 years compared to the untreated group, highlighting the immense potential of early intervention.
  • Clinical Trial Results: At the 18th Clinical Trials on Alzheimer's Disease conference, Eisai and Biogen showcased LEQEMBI's efficacy in low-amyloid group patients, demonstrating that continued treatment can extend the progression time from MCI to mild AD from 7.2 years to 9.7 years, saving 2.5 years.
  • Innovative Administration: The new subcutaneous formulation of LEQEMBI showed comparable drug exposure to intravenous dosing in clinical trials, with a weekly 500 mg regimen demonstrating good safety and efficacy while reducing infusion reaction risks for patients.
  • Regulatory Progress: The rolling supplemental Biologics License Application for LEQEMBI was completed in November 2025, expected to provide a new treatment option in the U.S. market, further solidifying Eisai and Biogen's leadership in Alzheimer's disease treatment.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Biogen Inc (BIIB) stock price today?

The current price of BIIB is 181.98 USD — it has increased 0.68 % in the last trading day.

arrow icon

What is Biogen Inc (BIIB)'s business?

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

arrow icon

What is the price predicton of BIIB Stock?

Wall Street analysts forecast BIIB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIIB is 184.00 USD with a low forecast of 149.00 USD and a high forecast of 250.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Biogen Inc (BIIB)'s revenue for the last quarter?

Biogen Inc revenue for the last quarter amounts to 2.53B USD, increased 2.79 % YoY.

arrow icon

What is Biogen Inc (BIIB)'s earnings per share (EPS) for the last quarter?

Biogen Inc. EPS for the last quarter amounts to 3.17 USD, increased 19.17 % YoY.

arrow icon

What changes have occurred in the market's expectations for Biogen Inc (BIIB)'s fundamentals?

The market is revising Upward the revenue expectations for Biogen Inc. (BIIB) for FY2025, with the revenue forecasts being adjusted by 0.22% over the past three months. During the same period, the stock price has changed by 29.37%.
arrow icon

How many employees does Biogen Inc (BIIB). have?

Biogen Inc (BIIB) has 7605 emplpoyees as of December 05 2025.

arrow icon

What is Biogen Inc (BIIB) market cap?

Today BIIB has the market capitalization of 26.71B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free